Drug intelligence / Profile preview

desaminotyrosine

Development stage
Preclinical
Lead developer
Xuzhou Medical University
Modality
Small Molecules
Administration
Oral
01

Overview

Desaminotyrosine (DAT) is a microbial metabolite produced by the gut microbiota, specifically through the degradation of dietary flavonoids by species such as *Flavonifractor plautii*. It acts as a potent immunomodulatory and tissue-protective agent, primarily by enhancing type I interferon (IFN-I) signaling through the interferon-alpha/beta receptor (IFNAR). DAT has demonstrated therapeutic potential in preclinical models for a variety of conditions, including viral infections (such as Influenza and Respiratory Syncytial Virus), obesity, graft-versus-host disease (GvHD), and cancer immunotherapy, where it enhances the efficacy of immune checkpoint inhibitors. Mechanistically, DAT also promotes intestinal regeneration via the mTORC1 and STING pathways and exhibits antioxidant properties by modulating the cellular NADP+/NADPH ratio, which contributes to its cardioprotective effects against myocardial ischemia/reperfusion injury.

Other names
3-(4-hydroxyphenyl)propionic acidphloretic acid3-(4-hydroxyphenyl)propanoic aciddihydro-p-coumaric acid
02

Targets

IFNAR (Interferon alpha/beta receptor)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on desaminotyrosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on desaminotyrosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call